0001193125-26-212481
SEC filingOutset Medical reported a revenue decline of 6.3% to $27.9M in Q1 FY2026, offset by improved gross margins (43.4%) and a 26.4% reduction in net loss — reflecting disciplined cost management amid persistent macroeconomic headwinds on acute care capital spending.
Our ability to achieve and sustain profitability depends on three interrelated factors: growing revenue while expanding gross margins; optimizing operating expenses; and improving working capital efficiency. In Q1 FY2026, gross margin expanded to 43.4%, supported by services associated with growth in our console installed base — a structural driver that enhances recurring revenue quality and margin resilience. This margin expansion occurred alongside a 6.3% decline in total revenue to $27.9M, reflecting continued pressure on hospital capital spending, particularly for new console placements.
Net income improved 26.4% year-over-year to -$19.0M, and diluted EPS rose 71.9% to -$1.03. Management attributes this improvement primarily to lower compensation expenses — a deliberate outcome of ongoing expense optimization efforts. This dynamic is central to our profitability framework: while revenue growth remains sensitive to macroeconomic conditions, controllable operating costs represent a near-term lever for loss mitigation. The absence of non-recurring charges present in prior periods — though not quantified in the authoritative packet — is consistent with the observed improvement in net income and EPS.
Net cash used in operating activities totaled -$12.8M, a meaningful improvement from -$25.7M in Q1 FY2025. This narrowing reflects progress in working capital management, including timing-related adjustments in accrued expenses and accounts receivable. Free cash flow was -$12.9M, incorporating minimal capital expenditures of $65K — signaling continued prioritization of operational flexibility over fixed-asset investment. This approach supports our long-term gross margin expansion and supply continuity strategies, including manufacturing localization in Mexico, which reduces production costs and improves operational responsiveness.
Our sales organization operates across two complementary teams: a capital sales team focused on new customer acquisition, and a clinical sales team driving utilization and fleet expansion at existing sites. The growth in service revenue — tied directly to installed base scale — reinforces the value of this dual-motion model. However, we acknowledge future risks, including potential supply chain constraints that could impair our ability to meet demand, affect customer satisfaction, and pressure operating margins. These dynamics underscore why profitability depends not only on top-line growth but also on disciplined execution across cost structure, working capital, and supply chain resilience.